TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05639803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGIFNα1b
Description: 100μg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGIFNα1b
Description: 100μg/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5ml/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5ml/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5ml/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5ml/vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5ml/vial
Study: NCT04512183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Fidelity Simulation
Description: Teaching strategy based on high-fidelity simulation, which simulates the reality of health care to promote meaningful learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-Fidelity Simulation
Description: Teaching strategy based on low-fidelity simulation, which simulates the reality of health care using less technological and less interactive mannequins.
Study: NCT03564249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniCap
Description: The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniCap
Description: The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
Study: NCT03246035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline. Patients will then be referred to a Geriatrics Assessment Team, who will provide individualized recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (Standard Care)
Description: For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
Study: NCT02457052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DATP
Description: Medical device allowing a custom sitting to help patients with swallowing disorders
Study: NCT02763748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic endoscopy combined surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic and endoscopic cooperative surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-arch laparoscopic and endoscopic cooperative surgery
Study: NCT02575183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varinecline (Chantix)
Description: A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Varenicline)
Description: A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
Study: NCT05869344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black bean protein hydrolysates (BPH)
Description: Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Commercial non-caloric beverage
Description: Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.
Study: NCT00317070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl sulfoxide
Description: intravesical installation 50 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IC Cocktail
Description: * Heparin 10,000 units~* Gentamicin 80 mg~* Hydrocortisone sodium succinate (Solucortef) 100 mg~* Lidocaine hydrochloride 1% 10 ml~* Sodium Bicarbonate 8.4% 5 ml
Study: NCT04476771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feliz-Mente (third generation psychotherapy)
Description: The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
Study: NCT04149522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel Film®
Description: As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepitel Film®
Description: As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
Study: NCT02265211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help App
Study: NCT01294254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10
Description: Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
Description: wound is covered conventionally by applying one half of the Mepilex cut
Study: NCT01713985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT02575183

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Therapy
Description: This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
Study: NCT01713985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermage
Description: Radiofrequency treatment focusing radiofrequency energy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermage
Description: Radiofrequency treatment focusing radiofrequency energy
Study: NCT04578145

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HIV self-testing among female sex workers
Description: Barriers faced by FSWs in terms of undergoing HIV blood test seemingly overcome through the implementation of alternative strategy of testing, by using OFT self-testing (Ora-Quick).~Ora-Quick test used in this study measures antibody in oral fluid of participants. The oral fluid is collected used a test swab from participant's gum by wiping upper and lower gums once. The specimen mixed with buffered developer solution in test tube. Test result will appear in a short time, by 20 to 40 minutes and leading to interpret.
Study: NCT00856752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Reference test: Single intravenous administration of 2 mg NRL972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
Study: NCT01709877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Description: Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystectomy
Description: Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
Study: NCT02466269

Intervention type: PROCEDURE
Intervention: The supratemporalis approach
Description: The supratemporalis approach was applied in treatment of diacapitular condylar fractures
Study: NCT02875522

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized, non-linear aerobic exercise training
Description: Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized, non-linear aerobic exercise training
Description: Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
Study: NCT03957590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Administered as 25 mg/m² IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as 25 mg/m² IV injection
Study: NCT00202852

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: 3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose \>=12.5 mg/week given orally or parenterally, maximum 20 mg/week
Study: NCT03957590

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Administered at a total dose of 50.4 Gy in 28 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Administered at a total dose of 50.4 Gy in 28 fractions
Study: NCT03094936

Intervention type: PROCEDURE
Group type: OTHER
Intervention: APC
Description: Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APC
Description: Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Suture Technique (OverStitch TM)
Description: OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
Study: NCT00865254

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Contingency Management
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Enhanced Contingency Management
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
Study: NCT03869073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Three pre-filled shrouded syringes for subcutaneous injection in abdomen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Three pre-filled shrouded syringes for subcutaneous injection in abdomen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preservative free 0.9% sodium chloride. Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
Study: NCT02870452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: 4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: 4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
Study: NCT01461577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE HOE 901
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02307526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tilt table test
Description: After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
Study: NCT01675037

Intervention type: OTHER
Intervention: Biological evaluation
Description: Complete hypothalamic-pituitary hormonal evaluation
Study: NCT02392871

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib (combination)
Description: Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
Study: NCT00227877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cSBA - New England, USA
Description: Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cSBA - Prague, CZR
Description: Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use.
Study: NCT05046210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LHA intervention
Description: The participants in the EG received 4 lessons from a LHA over 4 weeks. Four lessons were taught one-on-one once a week by a certified LHA at the participants' homes. The lessons including understand oral structure, learn oral self-care skills and oral function promotion, understand the status of oral self-care and the relationship between oral diseases and systemic diseases, understand swallowing dysfunction and safe eating skills and review.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral exercise intervention
Description: Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral exercise intervention
Description: Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.
Study: NCT03370081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPNOGRAPHY
Description: MONITORING OF CAPNOMETRY USING ETCO2 METHOD
Study: NCT02975154

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent therapy
Description: The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent therapy
Description: The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microcurrent therapy
Description: The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
Study: NCT03662334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid Acting insulin with pre-treatment of rHuPH20
Description: Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.